Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands

Prostate-specific membrane antigen (PSMA) is overexpressed in the majority of prostate cancer cells and is considered to be an important target for the molecular imaging and therapy of prostate cancer. Herein, we present the design, synthesis, and evaluation of 11 PSMA-binding radioligands with modi...

Full description

Bibliographic Details
Main Authors:	Fanny Lundmark, Gustav Olanders, Sara Sophie Rinne, Ayman Abouzayed, Anna Orlova, Ulrika Rosenström
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Pharmaceutics
Subjects:	prostate cancer PSMA linker optimisation molecular imaging SPPS structure-based design
Online Access:	https://www.mdpi.com/1999-4923/14/5/1098

Similar Items

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
by: Fanny Lundmark, et al.
Published: (2020-07-01)

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
by: Ayman Abouzayed, et al.
Published: (2023-09-01)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
by: Luisa M. Deberle, et al.
Published: (2020-05-01)

Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m
by: Ekaterina Bezverkhniaia, et al.
Published: (2024-03-01)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [<sup>68</sup>Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
by: Fanny Lundmark, et al.
Published: (2023-01-01)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2019-07-01)

Preclinical Evaluation of a Novel High-Affinity Radioligand [<sup>99m</sup>Tc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)
by: Ekaterina Bezverkhniaia, et al.
Published: (2023-12-01)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
by: Bogdan Mitran, et al.
Published: (2019-09-01)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01)

Safety-Catch Linkers for Solid-Phase Peptide Synthesis
by: Sikabwe Noki, et al.
Published: (2024-03-01)

PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties
by: Piotr Garnuszek, et al.
Published: (2021-03-01)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
by: Seiji Hoshi, et al.
Published: (2023-08-01)

Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient
by: David Parker, et al.
Published: (2023-04-01)

Streamlined Schemes for Dosimetry of <sup>177</sup>Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
by: Jens Kurth, et al.
Published: (2021-08-01)

Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
by: Joseph Lau, et al.
Published: (2022-08-01)

Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers
by: Erika Murce, et al.
Published: (2023-03-01)

Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
by: Daniel Groener, et al.
Published: (2023-01-01)

A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer
by: Szigeti András, et al.
Published: (2022-02-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
by: Nicolai Mader, et al.
Published: (2023-09-01)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
by: Philipp E. Hartrampf, et al.
Published: (2021-08-01)

A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [68Ga]Ga-PSMA-11
by: Steve S. Huang, et al.
Published: (2024-01-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01)

Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker
by: Caroline Burgard, et al.
Published: (2024-01-01)

Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
by: Felix Kind, et al.
Published: (2021-12-01)

Radiolabeled PSMA Inhibitors
by: Oliver C. Neels, et al.
Published: (2021-12-01)

Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
by: Marie-Christine Milot, et al.
Published: (2023-01-01)

Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT
by: Daniel Groener, et al.
Published: (2023-07-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with <sup>68</sup>Ga-PSMA PET/CT Features in Primary Staging
by: Luigia Vetrone, et al.
Published: (2023-03-01)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024-02-01)

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
by: Alessio Rizzo, et al.
Published: (2022-08-01)

A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications
by: K.S. Ajish Kumar, et al.
Published: (2022-12-01)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
by: Alexander D. Combes, et al.
Published: (2022-10-01)

Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
by: Yaniv Yechiel, et al.
Published: (2023-02-01)

Expanding the role of PSMA PET in active surveillance
by: Anika Jain, et al.
Published: (2023-04-01)

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Sebastian Gaal, et al.
Published: (2023-10-01)